Shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) have been assigned an average recommendation of “Hold” from the nine ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $11.80.

A number of analysts have recently issued reports on the stock. Stifel Nicolaus restated a “buy” rating and set a $13.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Tuesday. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Zacks Investment Research cut shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 30th. Piper Jaffray Companies assumed coverage on shares of Tetraphase Pharmaceuticals in a research note on Monday, August 28th. They set an “overweight” rating and a $14.00 target price for the company. Finally, BidaskClub upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd.

Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at 6.88 on Friday. The company’s market cap is $351.24 million. The stock’s 50 day moving average is $6.28 and its 200 day moving average is $7.26. Tetraphase Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.07). The company had revenue of $1.59 million for the quarter, compared to analyst estimates of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The business’s quarterly revenue was up 28.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.47) EPS. On average, equities analysts forecast that Tetraphase Pharmaceuticals will post ($2.54) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/15/tetraphase-pharmaceuticals-inc-ttph-receives-consensus-recommendation-of-hold-from-analysts.html.

In related news, insider Jacques Dumas sold 17,500 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total transaction of $105,000.00. Following the transaction, the insider now directly owns 17,500 shares of the company’s stock, valued at $105,000. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.50% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. AXA bought a new position in Tetraphase Pharmaceuticals during the second quarter worth about $132,000. Teza Capital Management LLC increased its position in Tetraphase Pharmaceuticals by 8.9% during the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 1,281 shares during the period. Citadel Advisors LLC increased its position in Tetraphase Pharmaceuticals by 18.6% during the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after acquiring an additional 2,496 shares during the period. Virtu KCG Holdings LLC bought a new position in Tetraphase Pharmaceuticals during the second quarter worth about $147,000. Finally, Voya Investment Management LLC increased its position in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 3,104 shares during the period. 41.73% of the stock is currently owned by institutional investors and hedge funds.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.